Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Written informed consent~* Subject aged ≥18 years of a primary, orthotopic liver allograft, from a living donor~* Subject negative for HIV~Incusion criteria at Randomization:~- Subject was initated on tacrolimus-based immunosuppressive regimen with steroids and other immunosuppression~Exclusion criteria:~* Subjects transplanted for acute liver failure~* HCV negativesubjects receiving a transplant from HCV positive donor~* Subjects receiving multiple solid organ (including multiple liver lobes/segments) or islet cell tissue transplants, or have previously received an organ or tissue transplant.~* Subjects receiving an ABO incompatible allograft.~* MELD-score \> 35 within 1 month prior to transplantation.~* Use of immunosuppressive or antibody induction agents not specified in the protocol.~* History of malignancy of any organ system (except hepatocellular carcinoma or localized basal cell carcinoma of the skin)~* Hepatocellular carcinoma with extrahepatic spread or macrovascular invasion~* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.~* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 2 weeks after the last dose of study medication~* History of hypersensitivity to any of the study drugs or to drugs with similar chemical class, or to any of the excipients~Exclusion criteria at Randomization:~* Any post-transplant history of thrombosis, occlusion or stent placement in any major hepatic arteries, hepatic veins, portal vein or inferior vena cava at any time during the run-in period prior to randomization.~* Subjects with a confirmed spot urine protein/creatinine ratio that indicates ≥ 1.0 g/24 hrs of proteinuria~* Subjects who have severe hypercholesterolemia (\>350 mg/dL; \>9.1 mmol/L) or hypertriglyceridemia (\>500 mg/dL; \>5.6 mmol/L) at randomization.~* Subjects with platelet count \< 30,000/mm3.~* Subjects with an absolute neutrophil count of \< 1,000/mm³ or white blood cell count of \< 2,000/mm³.~* Subjects with systemic infection requiring active use of IV antibiotics.~* Subjects requiring life support measures such as ventilation, dialysis, vasopressor agents.~* Subjects who require renal replacement therapy within 7 days prior to randomization.~* Subjects with detectable HBV DNA at time of randomization~* Subjects meeting the following criteria for acute rejection during the run in period:~  * Any acute rejection in the week prior to randomization.~ * 2 treated acute rejections.~ * Any rejection requiring antibody treatment.~ * Any severe cellular (and/or any humoral) rejection.~Long term extension for patients in Japan:~Inclusion criteria~* Written informed consent must be obtained before any extension specific assessment is performed.~* Ability and willingness to adhere to study regimen.~* Completed Month 24 visit of core study and continuously being treated with assigned regimen.~Exclusion criteria:~* Use of medication that is prohibited by the study protocol at Month 24.~* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.~* History of hypersensitivity to any of the study drugs or to drugs with similar chemical class, or to any of the excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus + reduced tacrolimus (Type: EXPERIMENTAL): Everolimus + reduced tacrolimus ± corticosteroids
- Standard tacrolimus (Type: ACTIVE_COMPARATOR): Standard tacrolimus ± corticosteroids

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete